Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.62 Billion USD | 7.51% |
| 2022 | 4.3 Billion USD | 7.99% |
| 2021 | 3.98 Billion USD | 20.51% |
| 2020 | 3.3 Billion USD | 2.23% |
| 2019 | 3.23 Billion USD | 16.17% |
| 2018 | 2.78 Billion USD | 8.73% |
| 2017 | 2.56 Billion USD | 18.17% |
| 2016 | 2.16 Billion USD | 15.44% |
| 2015 | 1.87 Billion USD | 10.56% |
| 2014 | 1.69 Billion USD | 11.44% |
| 2013 | 1.52 Billion USD | 8.41% |
| 2012 | 1.4 Billion USD | 18.19% |
| 2011 | 1.18 Billion USD | 14.45% |
| 2010 | 1.03 Billion USD | 12.62% |
| 2009 | 922.3 Million USD | 12.74% |
| 2008 | 818.1 Million USD | 14.76% |
| 2007 | 712.9 Million USD | 7.46% |
| 2006 | 663.4 Million USD | 6.43% |
| 2005 | 623.3 Million USD | 11.05% |
| 2004 | 561.3 Million USD | 12.01% |
| 2003 | 501.1 Million USD | 23.76% |
| 2002 | 404.9 Million USD | 10.03% |
| 2001 | 368 Million USD | -3.41% |
| 2000 | 381 Million USD | -13.21% |
| 1999 | 439 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.21 Billion USD | 3.13% |
| 2024 Q3 | 1.09 Billion USD | 0.31% |
| 2024 Q2 | 1.08 Billion USD | -10.37% |
| 2023 Q3 | 1.13 Billion USD | -4.78% |
| 2023 Q4 | 1.17 Billion USD | 4.13% |
| 2023 FY | 4.62 Billion USD | 7.51% |
| 2023 Q1 | 1.13 Billion USD | 3.64% |
| 2023 Q2 | 1.18 Billion USD | 5.05% |
| 2022 Q1 | 1.04 Billion USD | 2.13% |
| 2022 FY | 4.3 Billion USD | 7.99% |
| 2022 Q3 | 1.06 Billion USD | -3.56% |
| 2022 Q2 | 1.1 Billion USD | 6.01% |
| 2022 Q4 | 1.09 Billion USD | 2.37% |
| 2021 FY | 3.98 Billion USD | 20.51% |
| 2021 Q1 | 923.2 Million USD | 3.1% |
| 2021 Q3 | 998.5 Million USD | -4.15% |
| 2021 Q2 | 1.04 Billion USD | 12.84% |
| 2021 Q4 | 1.02 Billion USD | 2.17% |
| 2020 Q2 | 686.8 Million USD | -20.47% |
| 2020 Q1 | 863.6 Million USD | -2.74% |
| 2020 Q4 | 895.4 Million USD | 4.13% |
| 2020 Q3 | 859.9 Million USD | 25.2% |
| 2020 FY | 3.3 Billion USD | 2.23% |
| 2019 Q4 | 887.9 Million USD | 10.77% |
| 2019 Q1 | 761.2 Million USD | 2.45% |
| 2019 Q2 | 782.9 Million USD | 2.85% |
| 2019 Q3 | 801.6 Million USD | 2.39% |
| 2019 FY | 3.23 Billion USD | 16.17% |
| 2018 Q3 | 681.7 Million USD | -2.27% |
| 2018 FY | 2.78 Billion USD | 8.73% |
| 2018 Q2 | 697.5 Million USD | 5.49% |
| 2018 Q1 | 661.2 Million USD | 1.22% |
| 2018 Q4 | 743 Million USD | 8.99% |
| 2017 Q1 | 667.9 Million USD | 20.45% |
| 2017 FY | 2.56 Billion USD | 18.17% |
| 2017 Q4 | 653.2 Million USD | 7.4% |
| 2017 Q2 | 630.7 Million USD | -5.57% |
| 2017 Q3 | 608.2 Million USD | -3.57% |
| 2016 Q3 | 538 Million USD | -3.38% |
| 2016 Q2 | 556.8 Million USD | 7.7% |
| 2016 Q4 | 554.5 Million USD | 3.07% |
| 2016 Q1 | 517 Million USD | 4.4% |
| 2016 FY | 2.16 Billion USD | 15.44% |
| 2015 FY | 1.87 Billion USD | 10.56% |
| 2015 Q4 | 495.2 Million USD | 5.63% |
| 2015 Q2 | 458.2 Million USD | 0.86% |
| 2015 Q3 | 468.8 Million USD | 2.31% |
| 2015 Q1 | 454.3 Million USD | -0.72% |
| 2014 Q4 | 457.6 Million USD | 4.17% |
| 2014 Q3 | 439.3 Million USD | 3.63% |
| 2014 FY | 1.69 Billion USD | 11.44% |
| 2014 Q2 | 423.9 Million USD | 12.59% |
| 2014 Q1 | 376.5 Million USD | -3.59% |
| 2013 Q2 | 392.2 Million USD | 4.73% |
| 2013 FY | 1.52 Billion USD | 8.41% |
| 2013 Q4 | 390.5 Million USD | 6.72% |
| 2013 Q3 | 365.9 Million USD | -6.71% |
| 2013 Q1 | 374.5 Million USD | -2.65% |
| 2012 Q2 | 352.2 Million USD | 6.12% |
| 2012 Q1 | 331.9 Million USD | 6.86% |
| 2012 Q3 | 336.2 Million USD | -4.54% |
| 2012 FY | 1.4 Billion USD | 18.19% |
| 2012 Q4 | 384.7 Million USD | 14.43% |
| 2011 Q3 | 287.1 Million USD | -5.37% |
| 2011 Q4 | 310.6 Million USD | 8.19% |
| 2011 Q1 | 287.7 Million USD | 3.16% |
| 2011 FY | 1.18 Billion USD | 14.45% |
| 2011 Q2 | 303.4 Million USD | 5.46% |
| 2010 Q4 | 278.9 Million USD | 10.19% |
| 2010 FY | 1.03 Billion USD | 12.62% |
| 2010 Q1 | 241.9 Million USD | -1.27% |
| 2010 Q2 | 264.8 Million USD | 9.47% |
| 2010 Q3 | 253.1 Million USD | -4.42% |
| 2009 FY | 922.3 Million USD | 12.74% |
| 2009 Q4 | 245 Million USD | 7.83% |
| 2009 Q3 | 227.2 Million USD | -2.74% |
| 2009 Q2 | 233.6 Million USD | 7.9% |
| 2009 Q1 | 216.5 Million USD | 2.66% |
| 2008 Q2 | 214.6 Million USD | 10.68% |
| 2008 FY | 818.1 Million USD | 14.76% |
| 2008 Q4 | 210.9 Million USD | 6.14% |
| 2008 Q3 | 198.7 Million USD | -7.41% |
| 2008 Q1 | 193.9 Million USD | 0.26% |
| 2007 Q2 | 177.9 Million USD | 4.1% |
| 2007 Q3 | 170.7 Million USD | -4.05% |
| 2007 Q1 | 170.9 Million USD | 1.61% |
| 2007 Q4 | 193.4 Million USD | 13.3% |
| 2007 FY | 712.9 Million USD | 7.46% |
| 2006 Q1 | 164 Million USD | 2.44% |
| 2006 Q2 | 171.6 Million USD | 4.63% |
| 2006 FY | 663.4 Million USD | 6.43% |
| 2006 Q3 | 160 Million USD | -6.76% |
| 2006 Q4 | 168.2 Million USD | 5.13% |
| 2005 Q4 | 160.1 Million USD | 6.73% |
| 2005 Q1 | 152.9 Million USD | 4.8% |
| 2005 Q2 | 160.3 Million USD | 4.84% |
| 2005 Q3 | 150 Million USD | -6.43% |
| 2005 FY | 623.3 Million USD | 11.05% |
| 2004 Q2 | 142.2 Million USD | 4.33% |
| 2004 FY | 561.3 Million USD | 12.01% |
| 2004 Q4 | 145.9 Million USD | 6.57% |
| 2004 Q3 | 136.9 Million USD | -3.73% |
| 2004 Q1 | 136.3 Million USD | 4.6% |
| 2003 Q4 | 130.3 Million USD | 9.31% |
| 2003 Q1 | 123.4 Million USD | 5.11% |
| 2003 Q2 | 128.2 Million USD | 3.89% |
| 2003 Q3 | 119.2 Million USD | -7.02% |
| 2003 FY | 501.1 Million USD | 23.76% |
| 2002 FY | 404.9 Million USD | 10.03% |
| 2002 Q2 | 98.4 Million USD | 5.58% |
| 2002 Q4 | 117.4 Million USD | 22.42% |
| 2002 Q3 | 95.9 Million USD | -2.54% |
| 2002 Q1 | 93.2 Million USD | 1.64% |
| 2001 Q2 | 97.2 Million USD | 1.57% |
| 2001 Q3 | 83.4 Million USD | -14.2% |
| 2001 FY | 368 Million USD | -3.41% |
| 2001 Q4 | 91.7 Million USD | 9.95% |
| 2001 Q1 | 95.7 Million USD | 29.5% |
| 2000 FY | 381 Million USD | -13.21% |
| 2000 Q1 | 120 Million USD | 8.11% |
| 2000 Q2 | 104 Million USD | -13.33% |
| 2000 Q3 | 99.2 Million USD | -4.62% |
| 2000 Q4 | 73.9 Million USD | -25.5% |
| 1999 FY | 439 Million USD | 0.0% |
| 1999 Q4 | 111 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 79.105% |
| Allurion Technologies Inc. | 41.49 Million USD | -11045.384% |
| Artivion, Inc. | 229.17 Million USD | -1918.1% |
| Avanos Medical, Inc. | 379.7 Million USD | -1118.067% |
| Butterfly Network, Inc. | 16.85 Million USD | -27338.301% |
| Butterfly Network, Inc. | 16.85 Million USD | -27338.301% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | -223.122% |
| Boston Scientific Corporation | 9.89 Billion USD | 53.259% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -282947.736% |
| CONMED Corporation | 643.06 Million USD | -619.21% |
| Paragon 28, Inc. | 172.79 Million USD | -2576.644% |
| Glaukos Corporation | 239.13 Million USD | -1834.046% |
| Globus Medical, Inc. | 1.02 Billion USD | -353.297% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | -775.577% |
| Integer Holdings Corporation | 418.28 Million USD | -1005.695% |
| Medtronic plc | 19.45 Billion USD | 76.225% |
| Nevro Corp. | 290.06 Million USD | -1494.498% |
| Owlet, Inc. | 22.58 Million USD | -20376.38% |
| Penumbra, Inc. | 682.64 Million USD | -577.514% |
| Vicarious Surgical Inc. | -1.85 Million USD | 249560.626% |
| Smith & Nephew plc | 3.7 Billion USD | -24.966% |
| Sonendo, Inc. | 10.72 Million USD | -43035.609% |
| STERIS plc | 2.23 Billion USD | -107.028% |
| Stryker Corporation | 13.05 Billion USD | 64.581% |
| Vapotherm, Inc. | 28.28 Million USD | -16252.579% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 12.907% |